Total (N = 157) | NSVT (+) (N = 51) | NSVT (−) (N = 106) | P value | |
---|---|---|---|---|
Age (years) | 66.0 ± 12.1 | 65.7 ± 11.4 | 66.2 ± 12.5 | 0.80 |
Male | 135 (86%) | 45 (88%) | 90 (85%) | 0.57 |
NYHA | ||||
Class I | 21 (13%) | 8 (16%) | 13 (12%) | 0.62 |
Class II | 105 (67%) | 35 (68%) | 70 (66%) | |
Class III | 31 (20%) | 8 (16%) | 23 (22%) | |
VVI-ICD | 76 (48%) | 24 (47%) | 52 (49%) | 0.79 |
VDD/DDD-ICD | 31 (20%) | 9 (18%) | 22 (21%) | |
CRT-D | 50 (32%) | 18 (35%) | 32 (30%) | |
Hypertension | 113 (72%) | 39 (76%) | 74 (70%) | 0.38 |
Diabetes mellitus | 48 (31%) | 18 (35%) | 30 (28%) | 0.37 |
Serum creatinine | 1.29 ± 0.78 | 1.16 ± 0.31 | 1.35 ± 0.92 | 0.17 |
Hemoglobin (g/dL) | 13.8 ± 1.8 | 14.0 ± 1.6 | 13.8 ± 1.8 | 0.53 |
Atrial fibrillation | 60 (38%) | 16 (31%) | 44 (42%) | 0.22 |
Ischemic cardiomyopathy | 96 (61%) | 38 (75%) | 58 (55%) | 0.017 |
LVEF (%) | 31.5 ± 9.1 | 32.5 ± 10.4 | 31.1 ± 8.4 | 0.38 |
β Blocker | 150 (96%) | 49 (96%) | 101 (95%) | 0.82 |
ACEi or ARB | 146 (93%) | 47 (92%) | 99 (93%) | 0.78 |